A randomized pilot study of atractylenolide I on gastric cancer cachexia patients

Evidence-based Complementary and Alternative Medicine

Volumn 5, Issue 3, 2008, Pages 337-344

  Liu, Yi ^a   Jia, Zhongwu ^b   Dong, Lei ^a   Wang, Rui ^a   Qiu, Genquan ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b State Administration of Traditional Chinese Medicine of the People's Republic of China   (China)

Author keywords

Cytokine; Largehead atractylodes rhizome; Proteolysis inducing factor

Indexed keywords

ATRACTYLENOLIDE; ATRACTYLODES EXTRACT; BIOLOGICAL MARKER; CYTOKINE; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; INTERLEUKIN 1; INTERLEUKIN 6; PROTEIN DERIVATIVE; PROTEOLYSIS INDUCING FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; APPETITE; ARM CIRCUMFERENCE; ARTICLE; ATRACTYLODES; BODY WEIGHT; CACHEXIA; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MALE; MEDICAL RESEARCH; MEDICINAL PLANT; NAUSEA; NUTRITIONAL SUPPORT; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; RHIZOME; STOMACH CANCER; XEROSTOMIA;

EID: 51849162450     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1093/ecam/nem031     Document Type: Article

References (38)

1. Argilés JM, Alvarez BF, López-Soriano J. The metabolic basis of cancer cachexia. Med Res 1997;5:477-98.
2. Harvey KB, Bothe A, Blackburn GL. Nutritional assessment and patient outcome during oncological therapy. Cancer 1979;5:2065-9.
3. Luis FBP, Costa R. Exercise as a time-conditioning effector in chronic disease: a complementary treatment strategy. Evid Based Complement Alternat Med 2004;1:63-70.
4. Inagaki J, Rodriguez V, Bodey GP. Causes of death in cancer patients. Cancer 1974;33:568.
5. O'Gorman P, McMillan DC, McArdle CS. Impact of weight loss, appetite and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer 1998;32:76.
6. Li SZ. Ben-cao gang-mu, In: Jiangxi (ed). Vol. 2. Beijing: The People's Health Pub., House, 1977, 880-5.
7. Lu Zh. Ben-jing feng-yuan. Beijing: The China Press of Traditional Medicine, House, 1996, 29.
8. Yamahara J, Matsuda H, Huang Q, Li Y, Fujimura H. Intestinal motility enhancing effect of Atractylodes lancea rhizome. J Ethnopharmacol 1990;29:341-4.
9. Nogami M, Moriura T, Niahimura M, Kubo M. Studies on the origin, processing and quality of crude drugs. III. Pharmacological evaluations of the Chinese drug "zhu" in experimental stomach ulcer (3) effect of extract of Atractylodes lancea var. chinensis on gastric secretion. Yakugaku Zasshi 1985.
10. Nakai Y, Kido T, Hashimoto K, Kase Y, Sakakibara I, Higuchi M, et al. Effect of the rhizomes of Atractylodes lancea and its constituents on the delay of gastric emptying. J Ethnopharmacol 2003;84:51-5.
11. Mori H. Mechanisms of antitumor activity of aqueaes extracts from Chinese herbs: their immunopharmacological properties. Jan J Pharmacol 1989;49:423.
12. Kimura I. Medical benefits of using natural compounds and their derivatives having multiple pharmacological actions. Yakugaku Zasshi 2006;126:133-43.
13. Tsuneki H, Ma EL, Kobayashi S, Sekizaki N, Maekawa K, Sasaoka T, et al. Antiangiogenic activity of beta-eudesmol in vitro and in vivo. Eur J Pharmacol 2005;512:105-15.
14. Nisikawa Y, Watanabe Y, Seto T, Yasuda I. Studies on the components of Atractylodes. I. New sesquiterpenoids in the rhizone of Atractylodes lancea De Candolle. Yakugaku Zasshi 1976;96:1089-93.
15. Wang CC, Chen LG, Yang LL. Cytotoxic activity of sesquiterpenoids from Atractylodes ovata on leukemia cell lines. Planta Med 2002;68:204-8.
16. Endo K, Toguchi T, Toguchi F, Hikino H, Yamahara J, Fujimura H. Antiinflammatory principles of Atractylodes rhizomes. Chem Pham Bull 1979;27:2954-58.
17. Ching-Chiung W, Shyr-Yi L, Huey-Chuan Ch, Wen-Chi H. Pro-oxidant and cytotoxic activities of atractylenolide I in human promyeloleukemic HL-60 cells. Food Chem Toxicol 2006;44:1308-15.
18. Simons JP, Aaronson NK, Vansteenkiste JF, Velde GP, et al. Effects of medroxy progester one acetate on appetite, weight, and quality of life in advanced-stage non-hormone sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol 1996;14:1077-84.
19. Skudicky D. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensinconverting enzime inhibitors and carvedilol: results of a randomized study. Circulation 2001;103:1083-88.
20. Loprinzi CL, Schaid DJ, Dose AM. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11:152-4.
21. Karmali RA. Historical perspective and potential use of n-3 fatty acids in therapy of cancer cachexia. Nutrition 1996;12:S2-4.
22. Sauer LA, Dauchy RT, Blask DE. Mechanism for the antitumor and anticachetic effects of n-3 fatty acids. Cancer Res 2000;60:5289-95.
23. Sauer LA, Dauchy RT, Blask DE. Polyunsaturated fatty acids, melatonin,and cancer prevention. Biochem Pharmacol 2001;61:1455-62.
24. Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 1999;83:217-44.
25. Wigmore SJ, Fearon KCH, Maingay JP, Ross JA. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci 1997;92:215-21.
26. Barber MD, McMillan DC, Preston T, Ross JA, Fearon KCH. The metabolic response to feeding in weight-losing pancreatic cancer patients and its modulation by a fish oil-enriched nutritional supplement. Clin Sci 2000;98:389-99.
27. Nelson KA. The cancer anorexia-cachexia syndrome. Semin Oncol 2000;1:64-8.
28. Davis MP, Dickerson D. Cachexia and anorexia: cancer's covert killer. Support Care Cancer 2000;8:180-7.
29. Mantovani G, Maccio A, Lai P. Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine down-regulation and improvements on clinical symptoms. Crit Rev Oncog 1998;9:99-106.
30. Scott HR, McMillan DC, Crilly A, McArdle CS, Milroy R. The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer 1996;73:1560.
31. Fearon KCH, McMillan DC, Preston T, et al. Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann Surg 1991;213:26.
32. Mantovani G, Maccio A, Mura L. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000;78:554-61.
33. Rubin H. Cancer cachexia: its correlations and causes. Proc Natl Acad Sci USA 2003;100:5384-9.
34. Mantovani G, Maccio A, Mura L. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000;78:554-61.
35. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature 1996;379:739-42.
36. Lorite MJ, Thomspon MG, Drake JL, Carling GM, Tisdale J. Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer 1998;78:850-6.
37. Coodley GO, Loveless MO, Merrill J. The HIV wasting syndrome: a review. J Acquir Immune Defic Syndr 1994;7:681-94.
38. Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome. J Clin Oncol 1994;12:213-25.